19/08/2025
Our Mentor ๐ฅ
๐ฌ ๐ก๐ฒ๐ ๐ฃ๐๐ฏ๐น๐ถ๐ฐ๐ฎ๐๐ถ๐ผ๐ป ๐๐น๐ฒ๐ฟ๐ ๐ ๐
๐บ๐๐๐ฃ๐๐ โ ๐ท๐๐ ๐๐๐ ๐ ๐๐๐ ๐ต๐๐๐ ๐๐๐๐๐๐๐ ๐ท๐๐๐ ๐๐ก๐ฆ: ๐ด ๐๐๐๐๐๐๐ ๐
๐๐ฃ๐๐๐ค ๐๐ ๐กโ๐ ๐ผ๐๐๐๐๐ก ๐๐ ๐บ๐๐๐ฃ๐๐ โ ๐ท๐๐ ๐๐๐ ๐ ๐๐ ๐๐๐๐๐๐ ๐ป๐๐๐๐กโ
Iโm proud to share our latest work on which I mentored a passionate multidisciplinary team from Lebanon, Egypt, and Iraq.
๐๐๐๐ ๐ด๐ ๐ โ๐๐ข๐๐ฆ, ๐พโ๐๐๐๐ข๐ ๐ด๐ฟ ๐ฝ๐๐๐๐ค๐, ๐ป๐๐๐ฆ ๐ธ๐ก๐๐ฆ, ๐๐ข๐๐ก๐๐๐ ๐๐๐ก๐๐, ๐ผ๐๐๐โ๐๐ ๐ด. ๐ป๐๐ ๐ ๐๐, ๐ป๐๐ฆ๐ ๐๐๐๐๐ฆ ๐๐โ๐๐๐๐, ๐๐๐ ๐๐๐ ๐๐๐ ๐ท๐๐๐๐.
In this scoping review, we explored the interplay between Gravesโ disease and spinal bone mineral density (BMD) โ a crucial yet under-addressed aspect of endocrine and musculoskeletal health.
๐ก Key Highlights:
โ Gravesโ disease significantly reduces BMD, especially in the lumbar spine
โ Bone loss often persists even after achieving euthyroidism, with TSH receptor antibodies (TRAb) possibly having a link.
โ Anti-thyroid drug therapy alone may not fully restore BMD.
โ Combining bisphosphonates with anti-thyroid therapy shows better outcomes
โ High-risk populations (postmenopausal women, older men) need integrated management strategies.
This work underscores the need for holistic approaches in managing hyperthyroid autoimmune patients โ targeting not just hormone levels but also long-term skeletal health.
Link to our paper: https://www.sciencedirect.com/science/article/abs/pii/S1094695025000605?via%3Dihub
